F. Damond

发表

Performance of rapid tests for discrimination between HIV‐1 and/or HIV‐2 infections

S. Brunet, A. Gautheret-Dejean, Jonathan Bocobza, 2015, Journal of medical virology.

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

V. Trouplin, F. Mammano, F. Clavel, 2003, AIDS.

In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2011, Antimicrobial Agents and Chemotherapy.

Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load Quantification

F. Brun-Vézinet, C. Rouzioux, D. Descamps, 2010, Journal of Clinical Microbiology.

High frequency of selection of K65R and Q151M mutations in HIV‐2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

F. Brun-Vézinet, D. Descamps, G. Chêne, 2004, Journal of medical virology.

Hiv-2 molecular epidemiology.

C. Charpentier, D. Descamps, S. Matheron, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses.

F. Barré-Sinoussi, P. Roques, C. Apetrei, 2001, AIDS research and human retroviruses.

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, Antimicrobial Agents and Chemotherapy.

High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2015, AIDS.

CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort

F. Brun-Vézinet, G. Peytavin, G. Chêne, 2006, AIDS.

Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort

R. Salamon, F. Brun-Vézinet, G. Chêne, 2003, AIDS.

Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load Assay

F. Brun-Vézinet, D. Descamps, G. Chêne, 2005, Journal of Clinical Microbiology.

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, AIDS.

Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.

C. Rouzioux, S. Blanche, J. Warszawski, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

F. Brun-Vézinet, A. Calmy, A. van Sighem, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of freezing/thawing technique on sperm DNA integrity in HIV-1 patients

F. Vialard, J. Selva, C. Yazbeck, 2010, Journal of Assisted Reproduction and Genetics.

HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution

C. Charpentier, F. Collin, D. Descamps, 2021, Virus evolution.

Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of infectious diseases.

HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2014, AIDS.

Long-Lasting Persistence of Integrase Resistance Mutations in HIV-2-Infected Patients after Raltegravir Withdrawal

C. Charpentier, F. Brun-Vézinet, O. Delelis, 2011, Antiviral therapy.

Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Inserm, Shana M Augustin, C. Charpentier, 2020, Clinical Microbiology and Infection.

Quality Control Assessment of Human Immunodeficiency Virus Type 2 (HIV-2) Viral Load Quantification Assays: Results from an International Collaboration on HIV-2 Infection in 2006

F. Brun-Vézinet, B. Rodés, J. Albert, 2008, Journal of Clinical Microbiology.

Timing of Intermittent Seminal HIV-1 RNA Shedding in Patients with Undetectable Plasma Viral Load under Combination Antiretroviral Therapy

Y. Yazdanpanah, B. Pasquet, C. Estellat, 2014, PloS one.

Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO 1

C. Rouzioux, L. Mandelbrot, S. Blanche, 2010 .

Tropism distribution among antiretroviral-naive HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, C. Fagard, 2015, AIDS.

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2015, PloS one.

No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort

F. Brun-Vézinet, D. Descamps, G. Chêne, 2006, AIDS.

Selection of K65R Mutation in HIV-2-Infected Patients Receiving Tenofovir-Containing Regimen

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2004, Antiviral therapy.

A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes

J. Braun, E. Tuaillon, F. Damond, 2003, AIDS.

Human Immunodeficiency Virus Type 1 (HIV-1) Plasma Load Discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assays

F. Brun-Vézinet, D. Descamps, B. Roquebert, 2007, Journal of Clinical Microbiology.

HIV-1 subtypes and plasma RNA quantification.

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1999, AIDS.

V3 Serological Subtyping of Human Immunodeficiency Virus Type 2 Infection Is Not Relevant

F. Brun-Vézinet, F. Damond, J. Plantier, 2001, Journal of Clinical Microbiology.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

C. Charpentier, F. Brun-Vézinet, J. Capeau, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2021, Journal of Infection.

Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors

C. Leport, C. Chochillon, F. Damond, 1996, Antimicrobial agents and chemotherapy.

Impact of HIV-1 Genetic Diversity on Plasma HIV-1 RNA Quantification: Usefulness of the Agence Nationale de Recherches sur le SIDA Second-Generation Long Terminal Repeat-Based Real-Time Reverse Transcriptase Polymerase Chain Reaction Test

M. Peeters, C. Rouzioux, L. Ferradini, 2007, Journal of acquired immune deficiency syndromes.

Rare Selection of the K65R Mutation in Antiretroviral-Naive Patients Failing a First-Line Abacavir/Lamivudine-Containing Haart Regimen

F. Brun-Vézinet, D. Descamps, M. Ait-Khaled, 2006, Antiviral therapy.

In vitro Phenotypic Susceptibility to Nucleoside Reverse Transcriptase Inhibitors of HIV-2 Isolates with the Q151M Mutation in the Reverse Transcriptase Gene

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2005, Antiviral therapy.

Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors.

F. Barré-Sinoussi, P. Charneau, S. Brunet, 2004, The Journal of infectious diseases.

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, AIDS.

The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient.

M. Tulliez, N. Dupin, S. Regnier, 2007, AIDS.

Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/μl

J. Le bras, M. Guiguet, D. Costagliola, 2009, AIDS.

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

F. Brun-Vézinet, F. Dabis, E. Lazaro, 2008, AIDS.

Editorial Manager(tm) for Aids Manuscript Draft Title: Comparison of Viro-immunologic Markers Changes between Hiv-1 and Hiv-2 Infected Patients In

F. Brun-Vézinet, F. Dabis, E. Lazaro, 2022 .

A new human immunodeficiency virus derived from gorillas

François Simon, David L Robertson, Jean-Christophe Plantier, 2009, Nature Medicine.

V3 serotyping of HIV-1 infection: correlation with genotyping and limitations.

M. Peeters, E. Delaporte, C. Apetrei, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Diversity of the immunodominant epitope of gp41 of HIV-1 subtype O and its validity for antibody detection.

J. Eberle, L. Gürtler, L. Zekeng, 1997, Journal of virological methods.

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance

C. Charpentier, D. Descamps, Q. Le Hingrat, 2023, Viruses.

T cell changes after combined nucleoside analogue therapy in HIV primary infection.

G. Carcelain, B. Autran, P. Debré, 1999, AIDS.

Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

F. Brun-Vézinet, D. Descamps, S. Matheron, 2001, Journal of Clinical Microbiology.

New Sensitive One-Step Real-Time Duplex PCR Method for Group A and B HIV-2 RNA Load

C. Rouzioux, D. Descamps, M. Chaix, 2014, Journal of Clinical Microbiology.

The Human Immunodeficiency Virus Type 2 Vpx Protein Usurps the CUL4A-DDB1DCAF1 Ubiquitin Ligase To Overcome a Postentry Block in Macrophage Infection

A. Bergamaschi, F. Brun-Vézinet, S. Nisole, 2009, Journal of Virology.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, The Journal of antimicrobial chemotherapy.

Differences in proviral DNA load between HIV-1- and HIV-2-infected patients

F. Brun-Vézinet, G. Chêne, V. Lemée, 2008, AIDS.

One or two enzyme-linked immunosorbent assay tests on the first serum sample for initial diagnosis of HIV-1 infection?

F. Brun-Vézinet, C. Rouzioux, D. Costagliola, 2008, AIDS.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

F. Brun-Vézinet, B. Autran, G. Peytavin, 2009, AIDS.

Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir

C. Leport, F. Clavel, G. Peytavin, 2002, Antimicrobial Agents and Chemotherapy.

A new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain.

C. Charpentier, R. Tubiana, F. Collin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2010, Antimicrobial Agents and Chemotherapy.

Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.

C. Charpentier, D. Descamps, Q. Le Hingrat, 2018, Journal of virological methods.

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.

C. Charpentier, R. Tubiana, G. Peytavin, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genotypic resistance profiles of HIV-2-treated patients in West Africa

C. Charpentier, F. Brun-Vézinet, F. Dabis, 2014, AIDS.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

C. Charpentier, O. Delelis, J. Mouscadet, 2011, Retrovirology.

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572

C. Charpentier, F. Brun-Vézinet, R. Schinazi, 2010, AIDS.

Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1998, AIDS.

Human Immunodeficiency Virus Type 1 Subtype F Reverse Transcriptase Sequence and Drug Susceptibility

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1998, Journal of Virology.

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1997, Journal of virology.

High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort

Shana M Augustin, H. Goossens, C. Charpentier, 2021, Journal of Infection.

Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates

M. Sitbon, D. Descamps, S. Matheron, 2017, Scientific Reports.

HIV type 1 diversity and the reliability of the heteroduplex mobility assay.

F. Brun-Vézinet, M. Peeters, F. Barré-Sinoussi, 1998, AIDS research and human retroviruses.

Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france.

F. Brun-Vézinet, D. Robertson, C. Apetrei, 2001, Virology.

Evaluation of SARS-CoV-2 in semen, seminal plasma, and spermatozoa pellet of COVID-19 patients in the acute stage of infection

D. Descamps, E. Ruppé, Q. Le Hingrat, 2021, PloS one.

Women infected with human immunodeficiency virus type 1 have poorer assisted reproduction outcomes: a case-control study.

D. Luton, L. Mandelbrot, L. Epelboin, 2016, Fertility and sterility.

Evidence of Sexual Transmission of Zika Virus.

Eric D'Ortenzio, Yazdan Yazdanpanah, Diane Descamps, 2016, The New England journal of medicine.

HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man

C. Charpentier, D. Descamps, Q. Le Hingrat, 2018, Open forum infectious diseases.

The Two-Phase Emergence of Non Pandemic HIV-1 Group O in Cameroon

G. Lachenal, D. Robertson, Felix Feyertag, 2015, PLoS pathogens.

Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection.

F. Brun-Vézinet, C. Apetrei, M. Jolivet, 1997, AIDS research and human retroviruses.

Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients

J. Desenclos, F. Brun-Vézinet, G. Petitjean, 2007, AIDS.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of antimicrobial chemotherapy.

Plasma RNA Viral Load in Human Immunodeficiency Virus Type 2 Subtype A and Subtype B Infections

F. Brun-Vézinet, D. Robertson, D. Descamps, 2002, Journal of Clinical Microbiology.

Plasma RNA quantification and HIV-1 divergent strains.

J. Braun, F. Damond, J. Plantier, 2003, Journal of acquired immune deficiency syndromes.

Highly sensitive plasma RNA quantification by real-time PCR in HIV-2 group A and group B infection.

M. Resche-Rigon, M. Vray, F. Damond, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity

C. Charpentier, O. Schwartz, F. Collin, 2020, Journal of Virology.

Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1998, Journal of Clinical Microbiology.

Lack of screening test sensitivity during HIV‐1 non‐subtype B seroconversions

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1996, AIDS.

Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration

D. Minta, F. Dabis, C. Rouzioux, 2015, PloS one.

First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2)

C. Charpentier, D. Descamps, S. Gallien, 2021 .

An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHIEV2E Quality Control Study

G. Gottlieb, M. Wainberg, F. Brun-Vézinet, 2011, Journal of Clinical Microbiology.

Antiretroviral drug-resistant HIV-2 infection – a new therapeutic dilemma

S. Mandalia, F. Damond, R. Kamath, 2006, International journal of STD & AIDS.

Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

F. Brun-Vézinet, F. Mammano, G. Peytavin, 2005, Journal of Clinical Microbiology.

Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates

C. Charpentier, G. Peytavin, D. Descamps, 2022, AIDS.

Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.

V. Calvez, R. Tubiana, L. Mandelbrot, 2015, Antiviral therapy.

Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

A. Fischer, R. Tubiana, L. Cravello, 2020, The Journal of antimicrobial chemotherapy.

HIV type 1 diversity in northern Paris, France.

F. Brun-Vézinet, S. Saragosti, F. Damond, 1996, AIDS research and human retroviruses.

Interlaboratory quality control of total HIV‐1 DNA load measurement for multicenter reservoir studies

C. Delaugerre, C. Rouzioux, K. Sauné, 2017, Journal of medical virology.

An unusual HIV type 1 env sequence embedded in a mosaic virus from Cameroon: identification of a new env clade. European Network on the study of in utero transmission of HIV-1.

F. Barré-Sinoussi, P. Roques, D. Dormont, 1999, AIDS research and human retroviruses.

Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification.

F. Brun-Vézinet, D. Robertson, M. Worobey, 2004, AIDS research and human retroviruses.

Serological and virological characterization of HIV‐1 group O infection in Cameroon

F. Brun-Vézinet, F. Barré-Sinoussi, S. Saragosti, 1997, AIDS.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

F. Brun-Vézinet, P. Yeni, S. Matheron, 2009, AIDS.

Transmitted drug resistance in French HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2013, AIDS.

Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2013, AIDS.

Development and Evaluation of a DNA Enzyme Immunoassay Method for env Genotyping of Subtypes A through G of Human Immunodeficiency Virus Type 1 Group M, with Discrimination of the Circulating Recombinant Forms CRF01_AE and CRF02_AG

F. Brun-Vézinet, M. Peeters, E. Delaporte, 2002, Journal of Clinical Microbiology.

Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial

V. Calvez, F. Brun-Vézinet, C. Delaugerre, 2001, Antiviral therapy.

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2011, AIDS.

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2013, AIDS.

Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements

C. Charpentier, D. Descamps, Q. Le Hingrat, 2021, Journal of Virological Methods.

[HIV genetic diversity and its consequences].

F. Brun-Vézinet, D. Descamps, B. Roquebert, 2009, Pathologie-biologie.

Plasma viral RNA assay in HIV-1 group O infection by real-time PCR.

P. Roques, F. Damond, J. Plantier, 2003, Journal of virological methods.

Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure.

F. Brun-Vézinet, D. Robertson, C. Depienne, 2002, Virology.

Evaluation of the Roche Cobas TaqMan and Abbott RealTime Extraction-Quantification Systems for HIV-1 Subtypes

T. Bourlet, M. Vray, V. Lemée, 2007, Journal of acquired immune deficiency syndromes.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of HIV-1 Group O Genetic Diversity on Genotypic Resistance Interpretation by Algorithms Designed for HIV-1 Group M

C. Charpentier, F. Damond, J. Plantier, 2011, Journal of acquired immune deficiency syndromes.

Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2010, Antimicrobial Agents and Chemotherapy.

HIV-1 diversity in France, 1996–1998

F. Brun-Vézinet, H. Fleury, P. Roques, 2000 .

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

C. Charpentier, G. Carcelain, C. Delaugerre, 2021, European Journal of Clinical Microbiology & Infectious Diseases.

Nosocomial transmission clusters and lineage diversity characterized by SARS-CoV-2 genomes from two large hospitals in Paris, France, in 2020

V. Calvez, D. Descamps, F. Blanquart, 2022, Scientific Reports.

Corrigendum to ‘detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives’

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2021, Clinical Microbiology and Infection.

Proliferative, IFNγ and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection

F. Brun-Vézinet, G. Carcelain, B. Autran, 2006, AIDS.

SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department

D. Boutolleau, S. Burrel, D. Descamps, 2020, Journal of Infection.

New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification

C. Rouzioux, F. Collin, D. Descamps, 2017, Journal of Clinical Microbiology.

Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.

C. Charpentier, L. Weiss, F. Damond, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.

V. Calvez, C. Charpentier, D. Descamps, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Multicenter quality control of the detection of HIV‐1 genome in semen before medically assisted procreation

C. Pasquier, Y. Englert, L. Bujan, 2006, Journal of medical virology.

Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.

M. Sinet, C. Gaudebout, F. Chau, 2000, AIDS research and human retroviruses.

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2012, The Journal of antimicrobial chemotherapy.

Lymphoma in HIV-2-infected patients in combination antiretroviral therapy era

É. Oksenhendler, V. Meignin, L. Galicier, 2021, AIDS.

[Variability of human immunodeficiency virus type 1].

F. Brun-Vézinet, F. Damond, F. Simon, 1999, Bulletin de la Societe de pathologie exotique.

Integrase polymorphism and HIV-1 group O diversity.

P. Roques, B. Roquebert, D. Rousset, 2008, AIDS.